1301 Catherine Street
Ann Arbor, MI 48109
Available to mentor
The Green laboratory aims to accelerate progress in cancer care by effectively integrating immunotherapy with conventional cancer treatment modalities including surgery, chemotherapy, and radiotherapy. We seek to define and harness the determinants of inflammation which shape anti-tumoral immunity and influence cancer therapy efficacy. In particular, we focus on understanding the molecular, metabolic, and cellular checkpoints which alter CD8+ T effector cell trafficking and function in the tumor microenvironment. We conduct clinical, translational, and preclinical research that allow us to develop novel therapeutic strategies to better treat cancer patients.
Green Lab Rad Onc Profile Google Scholar
-
ResidencyUniversity of Michigan, Radiation Oncology, United States
-
MD, PhDIcahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, 2014
-
BSThe College of New Jersey, Ewing, 2006
-
Center MemberPrecision Health Initiative
-
Center MemberRogel Cancer Center
Radiobiology and Tumor immunology
The Green laboratory aims to accelerate progress in cancer care by effectively integrating immunotherapy with conventional cancer treatment modalities including surgery, chemotherapy, and radiotherapy. Our laboratory utilizes expertise in immunophenotyping and imaging to examine the role of programmed cell death and peripheral immune tolerance in cancer. We seek to define and harness the determinants of inflammation which shape anti-tumoral immunity and influence cancer therapy efficacy. In particular, we focus on understanding the molecular, metabolic, and cellular checkpoints which alter CD8+ T effector cell trafficking and function in the tumor microenvironment. We conduct clinical, translational, and preclinical studies that allow us to develop novel therapeutic strategies to better treat cancer patients.
-
Edwards DM, Sankar K, Alseri A, Jiang R, Schipper M, Miller S, Dess K, Strohbehn GW, Elliott DA, Moghanaki D, Ramnath N, Green MD, Bryant AK. Int J Radiat Oncol Biol Phys, 2024 Mar 15; 118 (4): 963 - 970.Journal ArticlePneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer.
DOI:10.1016/j.ijrobp.2023.09.050 PMID: 37793573 -
Li G, Choi JE, Kryczek I, Sun Y, Liao P, Li S, Wei S, Grove S, Vatan L, Nelson R, Schaefer G, Allen SG, Sankar K, Fecher LA, Mendiratta-Lala M, Frankel TL, Qin A, Waninger JJ, Tezel A, Alva A, Lao CD, Ramnath N, Cieslik M, Harms PW, Green MD, Chinnaiyan AM, Zou W. Cancer Cell, 2023 Feb 13; 41 (2): 304 - 322.e7.Journal ArticleIntersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy.
DOI:10.1016/j.ccell.2022.12.008 PMID: 36638784 -
Bell HN, Huber AK, Singhal R, Korimerla N, Rebernick RJ, Kumar R, El-Derany MO, Sajjakulnukit P, Das NK, Kerk SA, Solanki S, James JG, Kim D, Zhang L, Chen B, Mehra R, Frankel TL, Győrffy B, Fearon ER, Pasca di Magliano M, Gonzalez FJ, Banerjee R, Wahl DR, Lyssiotis CA, Green M, Shah YM. Cell Metab, 2023 Jan 3; 35 (1): 134 - 149.e6.Journal ArticleMicroenvironmental ammonia enhances T cell exhaustion in colorectal cancer.
DOI:10.1016/j.cmet.2022.11.013 PMID: 36528023 -
Kryczek I, Liu J, Green M, Chinnaiyan A, Cieslik M, Zou W. The Journal of Immunology, 2022 May 1; 208 (1_Supplement): 61.03 - 61.03.Proceeding / Abstract / PosterLiver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
DOI:10.4049/jimmunol.208.supp.61.03 -
Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, Chopra Z, El Naqa I, Zhou J, Bian Y, Jiang L, Tezel A, Skvarce J, Achar RK, Sitto M, Rosen BS, Su F, Narayanan SP, Cao X, Wei S, Szeliga W, Vatan L, Mayo C, Morgan MA, Schonewolf CA, Cuneo K, Kryczek I, Ma VT, Lao CD, Lawrence TS, Ramnath N, Wen F, Chinnaiyan AM, Cieslik M, Alva A, Zou W. Nat Med, 2021 Jan; 27 (1): 152 - 164.Journal ArticleLiver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.
DOI:10.1038/s41591-020-1131-x PMID: 33398162 -
Jiang CY, Zhao L, Green MD, Ravishankar S, Towlerton AMH, Scott AJ, Raghavan M, Cusick MF, Warren EH, Ramnath N. Sci Rep, 2024 Jan 3; 14 (1): 345Journal ArticleClass II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer.
DOI:10.1038/s41598-023-48546-y PMID: 38172168 -
Zhang Q, Jiang L, Wang W, Huber AK, Valvo VM, Jungles KM, Holcomb EA, Pearson AN, The S, Wang Z, Parsels LA, Parsels JD, Wahl DR, Rao A, Sahai V, Lawrence TS, Green MD, Morgan MA. JCI Insight, 2024 Feb 20;Journal ArticlePotentiating the radiation-induced type I interferon anti-tumoral immune response by ATM inhibition in pancreatic cancer.
DOI:10.1172/jci.insight.168824 PMID: 38376927 -
Worlikar T, Hall T, Zhang M, Mendiratta-Lala M, Green M, Cho CS, Xu Z. Int J Hyperthermia, 2024 41 (1): 2297650Journal ArticleInsights from in vivo preclinical cancer studies with histotripsy.
DOI:10.1080/02656736.2023.2297650 PMID: 38214171
